Skip to main content

stock

ROIV · Roivant Sciences Ltd.

What Roivant Sciences Ltd. reports to the SEC, read from its filings.

Open in the app

Price

The live ROIV price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on ROIV.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
722,323,015 as of 2026-07-31 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-7914.8%
Net
-3535.0%

Returns

ROE
-6.3%
ROA
-5.0%

Health

Current ratio
16.7x
Debt/equity
—

Deep value

NCAV
$4.36B
NCAV per share
$6.03
Price/NCAV
Locked
NNWC
$863.83M
NNWC per share
$1.20
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$1.44M—Gross profit: unreported by this company.-$365.99M-$189.84M
10-Q filed 2026-08-06
2026-03-31$2.52M—Gross profit: unreported by this company.$415.24M$302.99M
10-K filed 2026-05-20
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-12-31$2.00M—Gross profit: unreported by this company.-$339.15M-$265.89M
10-Q filed 2026-02-06
2025-09-30$1.57M—Gross profit: unreported by this company.-$306.23M-$113.52M
10-Q filed 2025-11-10
2025-06-30$2.17M—Gross profit: unreported by this company.-$284.92M-$223.35M
10-Q filed 2026-08-06
2025-03-31$7.57M—Gross profit: unreported by this company.-$284.96M-$206.47M
10-K filed 2026-05-20
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2024-12-31$9.02M—Gross profit: unreported by this company.-$274.38M$169.38M
10-Q filed 2026-02-06
2024-09-30$4.47M—Gross profit: unreported by this company.-$341.71M-$230.18M
10-Q filed 2025-11-10
Assets
$5.31B
Equity
$4.23B

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2026-03-31$8.26M-$515.07M-$299.77M-$758.56M
2025-03-31$29.05M-$1.00B-$171.98M-$844.05M
2024-03-31$32.71M$4.50B$4.35B-$766.65M
2023-03-31$31.53M-$906.76M-$1.01B-$856.08M
2022-03-31$55.29M-$1.35B-$845.26M-$695.16M
2021-03-31$23.80M-$1.07B-$809.23M-$557.94M

Company filings

events

  • Shareholder vote results

    Shareholder vote results
    Sep 188-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Sep 88-K
  • Other event

    Other event
    Aug 288-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Aug 278-K
  • Results

    Results
    Aug 68-K
  • Results

    Results
    May 208-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

  • Epperly Melissa B,

    Director

    Sale$640,861

    Oct 5, 6:05 PM ET

  • Venker Eric

    President & Immunovant CEO

    Sale$7,324,000

    Oct 2, 5:37 PM ET

  • Epperly Melissa B,

    Director

    Sale$196,230

    Sep 17, 6:43 PM ET

  • Fitzgerald Meghan

    Director

    Sale$203,152

    Sep 17, 6:42 PM ET

  • Fitzgerald Meghan

    Director

    Sale$798,000

    Sep 10, 9:00 PM ET

All insider trades for ROIV

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

All funds

News

Stories that named ROIV, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about ROIV.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about ROIV.

nakagai

Signals on ROIV come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the ROIV board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Roivant Sciences Ltd. (ROIV): SEC filings, financials and insider trades · Nakagai